Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Novel drugs and targets in MDS

In this interview from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University of Florence, Florence, Italy, gives an overview of the most exciting targeted therapies for myelodysplastic syndromes (MDS). She includes some oral therapies: enasidenib and ivosidenib, and roxadustat, which target IDH2, IDH1, and HIF respectively, all of which have the potential to improve outcomes and quality of life for MDS patients. She also discusses bispecific antibodies, highlighting an anti-CD33/anti-CD3 antibody which promises to eradicate MDS cells.